Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE CP versus EXTENDED PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE CP versus EXTENDED PHENYTOIN SODIUM.
DEPAKOTE CP vs EXTENDED PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
None Documented
None Documented
Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates.
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile.
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant